Publikationen, an denen er mitarbeitet JAVIER VAQUERO RODRÍGUEZ (14)

2023

  1. Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance

    Nature Reviews Gastroenterology and Hepatology, Vol. 20, Núm. 7, pp. 462-480

  2. TGFβ-induced circLTBP2 predicts a poor prognosis in intrahepatic cholangiocarcinoma and mediates gemcitabine resistance by sponging miR-338-3p

    JHEP Reports, Vol. 5, Núm. 12

2022

  1. Metabolic-associated fatty liver disease: From simple steatosis toward liver cirrhosis and potential complications. Proceedings of the Third Translational Hepatology Meeting, organized by the Spanish Association for the Study of the Liver (AEEH)

    Gastroenterologia y Hepatologia, Vol. 45, Núm. 9, pp. 724-734

2019

  1. Signalling networks in cholangiocarcinoma: Molecular pathogenesis, targeted therapies and drug resistance

    Liver International, Vol. 39, Núm. S1, pp. 43-62

2018

  1. MicroRNA-506 promotes primary biliary cholangitis–like features in cholangiocytes and immune activation

    Hepatology, Vol. 67, Núm. 4, pp. 1420-1440

2016

  1. Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)

    Nature Reviews Gastroenterology and Hepatology, Vol. 13, Núm. 5, pp. 261-280

2013

  1. Activation of the nuclear receptor FXR enhances hepatocyte chemoprotection and liver tumor chemoresistance against genotoxic compounds

    Biochimica et Biophysica Acta - Molecular Cell Research, Vol. 1833, Núm. 10, pp. 2212-2219

  2. Differential activation of the human farnesoid X receptor depends on the pattern of expressed isoforms and the bile acid pool composition

    Biochemical Pharmacology, Vol. 86, Núm. 7, pp. 926-939

  3. Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib

    Hepatology, Vol. 58, Núm. 3, pp. 1065-1073

  4. FXR-dependent and -independent interaction of glucocorticoids with the regulatory pathways involved in the control of bile acid handling by the liver

    Biochemical Pharmacology, Vol. 85, Núm. 6, pp. 829-838

2012

  1. Characterization of the role of ABCG2 as a bile acid transporter in liver and placenta

    Molecular Pharmacology, Vol. 81, Núm. 2, pp. 273-283

  2. Cisplatin-induced chemoresistance in colon cancer cells involves FXR-dependent and FXR-independent up-regulation of ABC proteins

    Molecular Pharmaceutics, Vol. 9, Núm. 9, pp. 2565-2576

  3. No correlation between the expression of FXR and genes involved in multidrug resistance phenotype of primary liver tumors

    Molecular Pharmaceutics, Vol. 9, Núm. 6, pp. 1693-1704

  4. Up-regulation of FXR isoforms is not required for stimulation of the expression of genes involved in the lack of response of colon cancer to chemotherapy

    Pharmacological Research, Vol. 66, Núm. 5, pp. 419-427